Intracranial Hemorrhage Following Anticoagulant Treatment in Denmark: Spontaneous Adverse Drug Reaction Reports Versus Real-World Data

Benedikte Irene Osmanski (), Astrid Blicher Schelde, Espen Jimenez-Solem, Martin Erik Nyeland and Henrik Horwitz
Additional contact information
Benedikte Irene Osmanski: Copenhagen University Hospital Bispebjerg and Frederiksberg
Astrid Blicher Schelde: Copenhagen University Hospital Bispebjerg and Frederiksberg
Espen Jimenez-Solem: Copenhagen University Hospital Bispebjerg and Frederiksberg
Martin Erik Nyeland: Copenhagen University Hospital Bispebjerg and Frederiksberg
Henrik Horwitz: Copenhagen University Hospital Bispebjerg and Frederiksberg

Drug Safety, 2022, vol. 45, issue 4, No 7, 379-388

Abstract: Abstract Introduction In Denmark, physicians are legally obliged to report serious adverse drug reactions (ADRs), such as intracranial hemorrhage (ICH) following anticoagulant (AC) treatment, to the Danish Medicines Agency. We were therefore puzzled to discover a high number of reports concerning ICHs following treatment with the direct oral anticoagulants (DOACs) dabigatran, rivaroxaban, and apixaban compared with warfarin. This was surprising, as all DOACs have been found to be associated with a lower risk of ICH compared with warfarin in phase III randomized controlled trials. Objectives The primary aim of the study was to estimate the level of underreporting of ICH as an ADR following treatment with warfarin, dabigatran, rivaroxaban, and apixaban. Methods This observational study covered a 5-year period (2014–2018). Using nationwide registries held by the Danish Health Data Authority, the number of users, exposure time in person-years, and related ICH events for each of the study drugs were estimated. Data on ADR-ICH reports were extracted from the interactive ADR overviews held by the Danish Medicines Agency. Results From 2014 to 2018, 97.0% of the identified warfarin-related ICH events were not reported as ADRs. For the DOACs, the level of underreporting ranged from 88.8 to 90.8%. Conclusion We found a heavy and differentiated level of underreporting of ICH as an ADR following treatment with the four study drugs.

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-022-01147-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:45:y:2022:i:4:d:10.1007_s40264-022-01147-6

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-022-01147-6

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().